Foghorn Therapeutics Inc. Common Stock vs. Eli Lilly & Co.
Foghorn Therapeutics Inc. Common Stock and Eli Lilly & Co. are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| FHTX | LLY | |
|---|---|---|
| Market Cap | $292.18 million | $1.02 trillion |
| Revenue (TTM) | $36.74 million | $79.67 billion |
| Net Income (TTM) | $-64,579,000 | $26.71 billion |
LLY leads on 3 of 3 size & scale factors.
Valuation
| FHTX | LLY | |
|---|---|---|
| P/E Ratio | — | 38.58 |
| Price / Book | -3.61 | 30.24 |
| Price / Sales | 7.95 | 12.86 |
FHTX leads on 2 of 2 valuation factors.
Profitability
| FHTX | LLY | |
|---|---|---|
| Net Margin | -175.78% | 33.53% |
| Return on Equity | 79.69% | 78.84% |
FHTX and LLY split the profitability factors evenly.
Dividend
| FHTX | LLY | |
|---|---|---|
| Dividend Yield | — | 0.60% |
| Payout Ratio | — | 23.23 |
FHTX and LLY split the dividend factors evenly.
Risk & Sentiment
| FHTX | LLY | |
|---|---|---|
| Short Interest | 0.03% | 1.29% |
FHTX leads on 1 of 1 risk & sentiment factors.
Dig deeper: FHTX overview, FHTX financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.